News

Novo Nordisk's former chief makes comeback to steer choice of new CEO
By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy ...
STAT5h
In the war for GLP-1 patients, Novo Nordisk leans on telehealth
Novo Nordisk's limited-time coupon on Wegovy was simultaneously promoted by telehealth companies Ro and Wegovy ...
Novo Nordisk joins finance’s great one-hit wonders
In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...
Healthcare Dive16h
Evernorth reaches deals with Novo Nordisk, Eli Lilly to cap GLP-1 copays
The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...
Why Novo Nordisk Stock Popped on Tuesday
Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...
Novo Nordisk Foundation pledges $57 million to WHO amid US funding gap
The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to ...
Explore more
Novo Nordisk CEO steps down as Wegovy maker faces increased competition
As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...
CEO of Novo Nordisk, maker of weight loss drug Wegovy, to step down in wake of share price drop
Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.
Novo Nordisk and US biotech company team up to create obesity pills
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...